Furthermore, IFNβ treatment of DCs from untreated MS patients down-regulated release of IL-23, but enhanced IL-27 gene expression in these cells, a cytokine that may inhibit Th17 differentiation [190,191]. Here, IFNB1 is linked to myeloid sarcoma.